Christian W. Scholz

Berlin, BE, Germany

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 43 publications

Outcomes of real-world complete responders after fixed-duration glofitamab in relapsed/refractory large B-cell lymphoma.

Outcomes of real-world complete responders after fixed-duration glofitamab in relapsed/refractory large B-cell lymphoma.

Journal: Haematologica

Published: October 17, 2025

Outcomes of real-world complete responders after fixed-duration glofitamab in relapsed/refractory large B-cell lymphoma.

Outcomes of real-world complete responders after fixed-duration glofitamab in relapsed/refractory large B-cell lymphoma.

Journal: Haematologica

Published: October 17, 2025

Inhibition of high CXCR4 with Motixafortide and absence of single-cell MRD predict outcome after AML consolidation.

Inhibition of high CXCR4 with Motixafortide and absence of single-cell MRD predict outcome after AML consolidation.

Journal: Blood

Published: October 14, 2025

Inhibition of high CXCR4 with motixafortide and absence of single-cell MRD predict outcome after AML consolidation.

Inhibition of high CXCR4 with motixafortide and absence of single-cell MRD predict outcome after AML consolidation.

Journal: Blood

Published: October 14, 2025

Tafasitamab, lenalidomide, and rituximab in relapsed or refractory follicular lymphoma (inMIND): a global, phase 3, randomised controlled trial.

Tafasitamab, lenalidomide, and rituximab in relapsed or refractory follicular lymphoma (inMIND): a global, phase 3, randomised controlled trial.

Journal: Lancet (London, England)

Published: March 26, 2025

PET/CT-based target volume definition in involved-site radiotherapy for treatment of early-stage nodal follicular lymphoma.

PET/CT-based target volume definition in involved-site radiotherapy for treatment of early-stage nodal follicular lymphoma.

Journal: Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al]

Published: September 18, 2024

Attrition between lines of therapy and real-world outcomes of patients with HER2-positive metastatic breast cancer in Europe: a cohort study leveraging electronic medical records.

Attrition between lines of therapy and real-world outcomes of patients with HER2-positive metastatic breast cancer in Europe: a cohort study leveraging electronic medical records.

Journal: Breast cancer research and treatment

Published: June 26, 2024

The addition of bortezomib to rituximab, high-dose cytarabine and dexamethasone in relapsed or refractory mantle cell lymphoma-a randomized, open-label phase III trial of the European mantle cell lymphoma network.

The addition of bortezomib to rituximab, high-dose cytarabine and dexamethasone in relapsed or refractory mantle cell lymphoma-a randomized, open-label phase III trial of the European mantle cell lymphoma network.

Journal: Leukemia

Published: December 20, 2023

International validation of a health-related quality-of-life questionnaire for Hodgkin lymphoma: the EORTC QLQ-HL27.

International validation of a health-related quality-of-life questionnaire for Hodgkin lymphoma: the EORTC QLQ-HL27.

Journal: Blood advances

Published: May 30, 2023

A German-Wide Systematic Study on Mobilization and Collection of Hematopoietic Stem Cells in Poor Mobilizer Patients with Multiple Myeloma prior to Autologous Stem Cell Transplantation.

A German-Wide Systematic Study on Mobilization and Collection of Hematopoietic Stem Cells in Poor Mobilizer Patients with Multiple Myeloma prior to Autologous Stem Cell Transplantation.

Journal: Transfusion medicine and hemotherapy : offizielles Organ der Deutschen Gesellschaft fur Transfusionsmedizin und Immunhamatologie

Published: February 21, 2023

Mobilization and Hematopoietic Stem Cell Collection in Poor Mobilizing Patients with Lymphoma: Final Results of the German OPTIMOB Study.

Mobilization and Hematopoietic Stem Cell Collection in Poor Mobilizing Patients with Lymphoma: Final Results of the German OPTIMOB Study.

Journal: Transfusion medicine and hemotherapy : offizielles Organ der Deutschen Gesellschaft fur Transfusionsmedizin und Immunhamatologie

Published: February 21, 2023

International validation of two EORTC questionnaires for assessment of health-related quality of life for patients with high-grade non-Hodgkin lymphoma (QLQ-NHL-HG29) and low-grade non-Hodgkin lymphoma (QLQ-NHL-LG20).

International validation of two EORTC questionnaires for assessment of health-related quality of life for patients with high-grade non-Hodgkin lymphoma (QLQ-NHL-HG29) and low-grade non-Hodgkin lymphoma (QLQ-NHL-LG20).

Journal: Cancer

Published: January 24, 2023

Showing 1-12 of 43

Last Updated: 09/26/2026